Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 30, 2023
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
[ Thu, Mar 30th 2023
] - WOPRAI
Thomas Shrader Maintained (ATHA) at Strong Buy with Decreased Target to $10 on, Mar 30th, 2023
Thomas Shrader of BTIG, Maintained "Athira Pharma, Inc." (ATHA) at Strong Buy with Decreased Target from $33 to $10 on, Mar 30th, 2023.
Thomas has made no other calls on ATHA in the last 4 months.
There is 1 other peer that has a rating on ATHA. Out of the 1 peers that are also analyzing ATHA, 0 agree with Thomas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Thomas
- Jason Butler of "JMP Securities" Reiterated at Buy and Held Target at $20 on, Friday, March 24th, 2023
